Please enable Javascript
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Alternative Intravesical Therapy and Patient Preferences in NMIBC
Sia Daneshmand, MD
Non-Muscle Invasive Urothelial Carcinoma
|
August 26, 2024
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
View More
NDA for Intravesical Mitomycin in NMIBC Based on Positive ENVISION Outcomes
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
August 19, 2024
If approved, mitomycin is anticipated to become the first FDA-approved treatment for LG-IR-NMIBC.
Read More
Bladder Preservation, Biomarkers for Detection, and BCG Predictors of Response in NMIBC
Sia Daneshmand, MD
Non-Muscle Invasive Urothelial Carcinoma
|
August 26, 2024
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
View More
Gemcitabine Plus Docetaxel for BCG-Naïve High-Risk NMIBC: Favorable 1-Year Follow-Up
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
July 31, 2024
BCG is ineffective in 30% to 77% of patients, and many experience disease recurrence within 5 years.
Read More
Reviewing the Role of PD-L1 in Patients With Urothelial Carcinoma
Katy Marshall
Muscle Invasive Urothelial Carcinoma
|
July 25, 2024
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
Read More
Updated ENVISION Data: UGN-102 Shows 82.3% Duration of Response in LG-IR-NMIBC
Sandip Prasad, MD, MPhil
Non-Muscle Invasive Urothelial Carcinoma
|
June 26, 2024
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
View More
ENVISION: Mitomycin Shows Promise as a Treatment for Patients With NMIBC
Katy Marshall
Non-Muscle Invasive Urothelial Carcinoma
|
June 18, 2024
UroGen began the process of a rolling New Drug Application to the FDA for mitomycin as a treatment for patients with NMIBC.
Read More
KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive NMIBC Who Do Not Respond to Pembrolizumab
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
June 6, 2024
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
View More
Final Results of CORE-001: Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
June 6, 2024
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
View More
Urinary Cell-Free DNA Predicts Measurable Residual Disease in High-Risk Bladder Cancer With High Accuracy
Brandon Twyford
Non-Muscle Invasive Urothelial Carcinoma
|
May 31, 2024
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
Read More
Cretostimogene Grenadenorepvec With Pembrolizumab Offers Best-in-Class CR, DOR, for NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
May 31, 2024
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
Read More
MoonRISe-1: TAR-210 for Intermediate-Risk NMIBC
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 28, 2024
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Read More
MoonRISe-1: Evaluating the Promise of TAR-210 for Intermediate-Risk NMIBC
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 21, 2024
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
View More
KEYNOTE-057: Pembrolizumab Monotherapy Shows Promise for Patients With High-Risk NMIBC
Katy Marshall
Non-Muscle Invasive Urothelial Carcinoma
|
May 14, 2024
The primary end point of the analysis of cohort B was 12-month disease-free survival.
Read More
Next-Generation Immunotherapy for NMIBC: QUILT 2.005 and QUILT 3.032
Patrick Soon-Shiong, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 10, 2024
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
View More
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Vikram M. Narayan, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
View More
Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up
Vikram M. Narayan, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
View More
Developing, Validating AI Biomarkers to Predict Outcomes in BCG-Treated NMIBC
Yair Lotan, MD
Non-Muscle Invasive Urothelial Carcinoma
|
May 7, 2024
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
View More
Intravesical EMDA/MMC Safe, Feasible for BCG-Unresponsive NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
May 3, 2024
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
Read More
Intravesical Gemcitabine, Docetaxel for BCG-Naïve NMIBC
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
May 3, 2024
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
Read More
Load More
Advertisement
Advertisement
Advertisement